Spectrum Presents Results of Poziotinib in (ZENITH20) Clinical Trial as 1L Treatment of NSCLC at ESMO TAT 2022
Shots:
- Cohort 4 of the (ZENITH20) trial evaluate the safety and efficacy of poziotinib (16mg, qd or 8mg, bid) in 70 patients with NSCLC with HER2 exon 20 insertion mutations
- The trial met its 1EPs i.e., the therapy showed an ORR (41%) in 70 treated patients including 1 CR as assessed by IRC, DCR (73%), DoR (5.7mos.), m-PFS (5.6mos.), 90% of patients had dose interruptions, 79% had reductions from the 16mg, qd starting dose while 64% had reductions from the 8mg BID starting dose, ORR of 50% in an evaluable patient population
- Additionally, the safety profile was consistent with the TKI class and tolerability, dose reductions and interruptions were less frequent with bid dosing
Ref: Businesswire | Image: Spectrum
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
